Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning

Thrombin is a key component for chemotherapeutic and antithrombotic therapy development. As the physiologic and pathologic roles of the light chain still remain vague, here, we continue previous efforts to understand the impacts of the disease-associated single deletion of LYS9 in the light chain. By combining supervised and unsupervised machine learning methodologies and more traditional structural analyses on data from 10 μs molecular dynamics simulations, we show that the conformational ensemble of the ΔK9 mutant is significantly perturbed. Our analyses consistently indicate that LYS9 deletion destabilizes both the catalytic cleft and regulatory functional regions and result in some conformational changes that occur in tens to hundreds of nanosecond scaled motions. We also reveal that the two forms of thrombin each prefer a distinct binding mode of a Na+ ion. We expand our understanding of previous experimental observations and shed light on the mechanisms of the LYS9 deletion associated bleeding disorder by providing consistent but more quantitative and detailed structural analyses than early studies in literature. With a novel application of supervised learning, i.e. the decision tree learning on the hydrogen bonding features in the wild-type and ΔK9 mutant forms of thrombin, we predict that seven pairs of critical hydrogen bonding interactions are significant for establishing distinct behaviors of wild-type thrombin and its ΔK9 mutant form. Our calculations indicate the LYS9 in the light chain has both localized and long-range allosteric effects on thrombin, supporting the opinion that light chain has an important role as an allosteric effector.

Abstract aus PubMed (NCBI) für den zitierten Eintrag, in der Originalsprache wiedergegeben. Maßgeblich ist die Fassung der Originalpublikation.

Das Abstract wird nicht übersetzt, damit die eigene Wortwahl der Autoren erhalten bleibt.

Molecular dynamics simulations plus machine learning show that deleting LYS9 from thrombin's light chain destabilizes the catalytic cleft and regulatory regions, alters Na+ binding, and affects seven key hydrogen-bond pairs, illuminating the mechanism of an associated bleeding disorder.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Weitere begutachtete Studien in der Kategorie „Arzneimittelentwicklung“.

• Hirudotherapie in Medizin und Zahnmedizin — Jha K et al. (2015)
• Blutegeltherapie: eine Geschichte — Hyson J (2005)
• Hirudine der asiatischen medizinischen Blutegelart Hirudinaria manillensis: gleich und doch verschieden — Lukas P et al. (2019)
• Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia — Lu Z et al. (2018)
• Molekulardynamische und pharmakologische Untersuchungen an durch Protein-Engineering erzeugten Hirudin-Varianten von Hirudinaria manillensis und Hirudo medicinalis — Sun Y et al. (2022)
• Zellfreie Synthese der Hirudin-Variante 1 des blutsaugenden Egels Hirudo medicinalis — Wüstenhagen D et al. (2020)
• Produktion von Hirudin-Varianten durch gentechnisch veränderte mikrobielle Zellfabriken — Zhang J, Lan N (2018)
• Hirudin bei heparininduzierter Thrombozytopenie — Lubenow N, Greinacher A (2002)
• Hirudin verbessert die diabetische Nephropathie durch Hemmung der Gsdmd-vermittelten Pyroptose — Han J et al. (2023)
• Hirudin als alternatives Antikoagulans – eine historische Übersicht — Markwardt F (2002)

Alle von der ASH analysierten Studien →